Accuracy Of Contrast Enhanced Mamography in Predicting Response of Breast Cancer Post Neoadjuvant Chemotherapy
Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05141279
Collaborator
(none)
50
25
Study Details
Study Description
Brief Summary
The aim of this work to evaluate the accuracy of contrast enhanced spectral mamography in predicting the response to NAC and assessment of residual disease in breast cancer patients
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
This a prospective series ,will be performed for 50 patients diagnosed by biopsy as breast cancer who will be scheduled for surgery after completing the full coarse of neoadjuvant chemotherapy
Study Design
Study Type:
Observational
Anticipated Enrollment
:
50 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Contrast Enhanced Mamography in Predicting Response of Breast Cancer Post Neoadjuvant Chemotherapy
Anticipated Study Start Date
:
Dec 1, 2021
Anticipated Primary Completion Date
:
Dec 1, 2023
Anticipated Study Completion Date
:
Jan 1, 2024
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
1 Stable |
|
2 Partial response |
|
3 Moderate response |
|
4 Excellent response |
|
5 Complete response |
Outcome Measures
Primary Outcome Measures
- Accuracy of contrast enhanced spectral mamography in the predicting of pathological response to NAC and assessment residual disease in breast cancer patients [Basline]
Secondary Outcome Measures
- Assess best imaging modalities in pedict post neoadjuvant response [Baseline]
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
-
patient confirmed diagnosed by early breast cancer decided to received neoadjuvant treatment
-
locally advanced breast cancer
-
operable metastatic breast cancer
Exclusion Criteria:
-
patient not candidate for NAC
-
contrast allergy
-
renal impairment
-
pregnancy
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Assiut University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
DMAhmed,
Doaa Mahmoud Ahmed,
Assiut University
ClinicalTrials.gov Identifier:
NCT05141279
Other Study ID Numbers:
- CESM in breast cancer
First Posted:
Dec 2, 2021
Last Update Posted:
Dec 2, 2021
Last Verified:
Nov 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: